Previous 10 | Next 10 |
Unum Therapeutics (NASDAQ: UMRX ): Q4 GAAP EPS of -$0.29 beats by $0.05 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma - - First Solid Tumor Trial, ATTCK-34-01, Initiated in HER2+ Advanced Cancers – ...
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel T cell technology platforms, today announced that the company will ho...
The following slide deck was published by Unum Therapeutics Inc. in conjunction with this Read more ...
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson, ...
Gainers: vTv Therapeutics (NASDAQ: VTVT ) +169% . Cool Holdings (NASDAQ: AWSM ) +58% . Estre Ambiental (NASDAQ: ESTR ) +34% . PLx Pharma (NASDAQ: PLXP ) +31% . OPKO Health (NYSEMKT: OPK ) +30% . Quantum Corporation (NYSE: QTM ) +28% . Mersana Therapeutics (NASDAQ: MRSN ) +28% ...
88 companies went public in 2018 with venture capital backing. Excluding Spotify's (SPOT) direct listing, the group raised $15 billion in the IPO market. Venture exits accounted for 46% of 2018's total, and VC deal count and proceeds reached a 4-year high. The pickup in activity was driven by ...
NEW YORK, Dec. 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Synopsys, Inc. (NASDAQ:SNPS), Unum Therapeutics Inc. (NASDAQ:UMRX), HD Su...
- Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose Level 2 - - No SAEs of Cytokine Release Syndrome or Neurological Events Observed in Dose Levels 1 or 2 - - Currently Dosing Patients at Dose Level 3 - &...
CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in combination with SEA-BCMA in patients with relapsed/refractory multiple myeloma (r/r MM) at the Ameri...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...